IHS (NYSE: IHS) reported earnings yesterday. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Feb. 29 (Q1), IHS missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share contracted significantly.

Gross margins expanded, operating margins contracted, net margins dropped.

Revenue details
IHS logged revenue of $342.7 million. The 10 analysts polled by S&P Capital IQ anticipated revenue of $356.7 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $295.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.77. The 10 earnings estimates compiled by S&P Capital IQ forecast $0.82 per share on the same basis. GAAP EPS of $0.35 for Q1 were 26% lower than the prior-year quarter's $0.47 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 57.2%, 70 basis points better than the prior-year quarter. Operating margin was 12.4%, 240 basis points worse than the prior-year quarter. Net margin was 6.8%, 360 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $383.9 million. On the bottom line, the average EPS estimate is $0.94.

Next year's average estimate for revenue is $1.54 billion. The average EPS estimate is $3.97.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 76 members out of 87 rating the stock outperform, and 11 members rating it underperform. Among 34 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give IHS a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on IHS is outperform, with an average price target of $93.20.